Cencora, Inc. (COR)
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Cencora (COR) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Walgreens Sells Another Stake In Distributor Cencora For $300 Million
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said Thursday night.
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
Cencora (COR) Q1 2025 Earnings Call Transcript
Cencora Inc. (NYSE:COR ) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Robert Mauch - President, Chief Executive Officer James Cleary - Executive Vice President, Chief Financial Officer Bennett Murphy - Senior Vice President, Head of Investor Relations Conference Call Participants Michael Cherny - Leerink Partners Lisa Gill - JP Morgan Elizabeth Anderson - Evercore ISI Steven Valiquette - Mizuho Securities Eric Percher - Nephron Research Daniel Grosslight - Citi Stephen Baxter - Wells Fargo Charles Rhyee - TD Cowen Allen Lutz - Bank of America George Hill - Deutsche Bank Erin Wright - Morgan Stanley Kevin Caliendo - UBS Eric Coldwell - Baird Operator Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I'll be your Operator today.
Here's What Key Metrics Tell Us About Cencora (COR) Q1 Earnings
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) Surpasses Q1 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.50 per share. This compares to earnings of $3.28 per share a year ago.
Cencora raises 2025 profit forecast on specialty drug demand
Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stay Ahead of the Game With Cencora (COR) Q1 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
